Our presence at ASN was a powerful showcase of Vivance’s mission to revolutionize kidney care. From impressive data to innovative product showcasing and the unwavering dedication of our team, this event highlighted the heart of Vivance’s journey. Here are some key moments from the conference:

Viva Kompact Pre-Pivotal Study Insights: Our Viva Kompact pre-pivotal study data underscored a major milestone—no serious device-related safety events. In addition to meeting the primary endpoint of the study, we also resolved key improvements identified in the First-in-Human trial, achieving promising results in electrolyte balance, UF, and clearance. Notably, the study included a few patients who, for the very first time in the history of wearable PD, completed up to 30 days of use at home. Plus, we’ve learned what to fine-tune as we step into the pivotal phase.

Introducing Viva Komfort: We unveiled our innovative On-Demand Dialysate Generation Prototype with an integrated APD device, thoughtfully designed to enhance accessibility and ensure long-term sustainability. Prioritizing user experience and treatment cost, this device aims to make home PD more practical and appealing. The response was overwhelming!

ASN 2024 was just one key pit stop in our journey of continuously pushing the boundaries of kidney care innovation. Keep watching this space for more updates!

Note: Vivance’s products are currently in the R&D stage and are not commercially available anywhere.